MedTrace Logo

Olmesartan in Essential Hypertension

NCT00185172 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2333

Last updated 2008-04-29

No results posted yet for this study

Summary

To test the efficacy and safety of olmesartan in patients with essential hypertension.

Conditions

  • Essential Hypertension

Interventions

OTHER

placebo

Placebo oral tablets for 2 weeks

DRUG

olmesartan medoxomil

olmesartan medoxomil oral tablets for 8 weeks

DRUG

olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets

olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets

Sponsors & Collaborators

  • Sankyo Pharma Gmbh

    lead INDUSTRY

Principal Investigators

  • Prof. Michael Bohm, MD · Universitatskliniken des Saarlandes, Homburg, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • Austria
  • Germany
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185172 on ClinicalTrials.gov